Tyler Humphrey

🚀 Attention Investors and Healthcare Leaders! 🚀 R3i are thrilled to celebrate StratifiCare™ Pte. Ltd.'s CEO, Anthony Chua, who just landed in Dallas, Texas, to accelerate the progress of two revolutionary personalized medicine diagnostics: 🌟 Stratifiden - The world's first severe dengue prognostic that reduces unnecessary hospitalization by 67%, easing the emotional and financial burden on families. 🌟 Stratifirey - The world's first liver cancer diagnostic that predicts patient response to Y90 RE treatment, allowing clinicians to make informed decisions and reduce the agonizing 3 to 6-month wait for results. StratifiCare's journey is a testament to perseverance and innovation. To develop these groundbreaking products, it secured $35M in non-dilutive capital and less than $1M in venture capital. Anthony Chua's unwavering determination teaches us the power of persistence and the impact of every step forward. A special thank you to David Jacobson for welcoming StratifiCare™ Pte. Ltd. into our Texas triangle and the SMU Cox School of Business community. 💡 Investors and hospital administrators, this is your chance to be part of a transformative journey in personalized medicine. Reach out and learn how you can support and benefit from these pioneering advancements. Together let's accelerate impact 💡 NUS Overseas Colleges National University of Singapore Singapore Economic Development Board (EDB) #HealthcareInnovation #PersonalizedMedicine #DengueDiagnostic #LiverCancerDiagnostic #StratifiCare #InvestmentOpportunities #HealthcareLeaders #MedicalBreakthroughs #Valuebasedcare Enterprise Singapore

25

#VentureCapital is flowing again into #biotech, but the slower pace of investments can impact the ways CEOs are being compensated.   CEO & Managing Partner Leslie Loveless offers her perspectives on the topic in this insightful new article in BioSpace.    She explains that pay packages and one’s appetite for risk help determine whether a CEO candidate is right for the job.   “There are a lot of people that are very drawn to the higher-risk, higher-reward scenario that you see in biotech, and if that is what you’re drawn to, great. Go for it,” Loveless said. “But if that is not how you are wired, if that’s not in your DNA, then I would encourage folks to appreciate that about themselves. And don’t go into a negotiation with a biotech wanting them to pay you like they are Big Pharma, because they’re not going to. That’s not how they’re wired.”   We appreciate the coverage, Angela Gabriel!   #lifesciences #executivesearch

28

2 Comments

For #biopharma professionals, understanding the #patientjourneys of missed and underdiagnosed patients can be challenging. See how OM1, Inc. partnered with a leading biopharma company to leverage #AI and #realworlddata, uncovering and gaining deeper insights into underdiagnosed patients with treatment-resistant depression—individuals frequently missed by conventional #RWD approaches. #realworldoutcomes #rwe #realworldevidence #dataquality #patientoutcomes #access #marketaccess #medicalaffairs #heor #healtheconomics #patientcentricity #outcomesresearch #bigdata #ai #neuroscience #neurology #psychiatry #personalizedmedicine #predictiveanalytics #healthcare #pharma

7

Our cofounders chatted with San Diego Business Journal about our recent #AACR24 data showing our lead drug candidate works across many cancer types to kill tumor cells but leave healthy cells alone – as well as how our upcoming clinical trial could quickly yield proof-of-concept data. Read the article here (subscription may be required): https://lnkd.in/gR-rCQzE #cancer #cancers #tumor #tumors #oncology #neutrophil #immunity #innatepathway #anticancer #clinicaltrials #skincancer #headandneckcancer #breastcancer

25

M13 is thrilled to lead the Series A in RadiantGraph which is focused on personalization in healthcare. As we continue to invest in early stage companies it is abundantly clear that the biggest indicator of success is the founder and his or her ability to execute on their vision of the future. In this case, I don't think I have seen much better founder-market fit than we have with founder and CEO Anmol Madan. We believe in his vision: in order to have the best patient outcomes in healthcare we need increased personalization and AI is the breakthrough to get us there. Anmol started one of the pioneering digital health companies Ginger and then was Chief Data Scientist at Livongo and Teledoc. He has done it all: early stage, late stage, public company. And he deeply understands the nuances of the healthcare market from all angles which is critical for success. While there are many players building healthcare-specific AI capabilities, RadiantGraph is focused on outcomes: The platform is already processing personalization models for more than 3.5 million people, despite launching just last year. Excited to partner with my friend Adam D'Augelli and the great True Ventures again and Morgan Blumberg who has been deep in the healthcare market with me for many years. More on our thesis in the blog below. https://lnkd.in/evDDmC3W

72

4 Comments

🚨 Healthcare Tech Innovation Alert 🚨 Mendaera, Inc., a San Mateo-based healthcare tech company developing a handheld robotic interventional platform, has raised an impressive $73M in Series B funding! 💰 The round was led by Threshold Ventures, with backing from Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health, Inc.). 🏦 Mendaera is using this funding to scale robotics and AI across mainstream medical procedures, making cutting-edge technology more accessible across medical specialties and sites of service. Founded by CEO Josh DeFonzo, Mendaera’s platform integrates: • Robotics 🤖 • AI 🧠 • Real-time imaging 🖼️ • Virtual connectivity 🌐 Their goal? To empower healthcare providers and systems to meet the growing demand for needle-based interventions more efficiently. 🏥💉 In 2023, Mendaera made big moves: • Acquired telepresence technology from Avail Medsystems has moved to Mendaera, Inc. to expand its virtual connectivity portfolio 📡 •Entered into a commercial agreement with Butterfly Network, Inc., a leader in point-of-care ultrasound tech 🦋 This is just the beginning for Mendaera as they revolutionize the intersection of robotics and healthcare! 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs #Mendaera #HealthcareInnovation #MedTech #Robotics #SeriesBFunding #AI #VirtualConnectivity #ThresholdVentures #FredMoll #TechNews #ButterflyNetwork #FutureTechly

2

In our latest publication in Health, Management, Policy, and Innovation – "Why AI Is Good for Our Health but May Hurt Our Wallets," we examine how current regulatory frameworks, reimbursement structures, and business models for AI in healthcare are decoupled, creating an environment in which AI may significantly increase costs without necessarily improving outcomes. We recommend three interconnected reforms to unlock the full potential of healthcare AI: (1) Rigorous pre- and post-deployment evaluation to verify proposed clinical value, (2) Development of assessment standards through shared guidelines, and (3) Strategic alignment of AI deployment modalities with sustainable business models – "modality-business model-market" fit 👉 https://lnkd.in/d8NiczyM Sneha Shah Jain, MD, MBA, Clinical Professor and Kevin Schulman Professor of Medicine at Stanford University, Nigam Shah, Chief Data Scientist, Michael Pfeffer, Chief Information and Digital Officer, and Linda Hoff Chief Financial Officer at Stanford Health Care

106

9 Comments

Platforms are in, point solutions are out as the healthcare AI category leaders come into focus this year. In conversation with Shelby Livingston at Endpoints News, I shared: 1. Why AI-first companies have the greatest platform potential and heuristics for identifying these opportunities at the earliest stages, 2. How companies are differentiating through co-development and distribution partnerships with leading healthcare institutions, and 3. Strategies for navigating anemic budgets and constrained market sizes through business model innovation such as AI-enabled services and pay for performance models Read more here: https://lnkd.in/dJWqv_zC Bessemer Venture Partners Abridge #healthcare #lifesciences #AI #generativeAI

258

14 Comments

Othman Laraki and Color catalyzing positive change in a segment that is 19% of US GDP. Everyone knows that health care costs are way out of line in the USA compared to other developed countries where costs are lower and outcomes are better. We need to change the incentive systems and acclerate the move toward 'value based care'. That, and more efficient and accurate diagnosis and delivery of the RIGHT care, is really necessary for the USA's balance sheet to somday trend in the right direction.

39

2 Comments

Newest episode of #HealthAndVeritas with guest, Mitesh Rao, MD, CEO of OMNY Health talking about democratizing access to healthcare data and improving health through more reliable information. Harlan Krumholz talks about "The business case for quality: estimating lives saved and harms avoided in a value-based purchasing model" an article in Health Affairs Scholar that returns us to the uncomfortable domain of asking why our "system" doesn't do more to save lives and improve health outcomes. I talk about Marijuana. I am concerned that we are watching a slow moving catastrophe due to the desire to decriminalize and reduce controls over Cannabis and THC-containing products (which is good) while paying too little attention to quality and regulations. Listen to the pod and tell me what YOU think. And please post your comments, tell a friend, and rate and review us on your favorite podcast app. Yale School of Management Yale School of Public Health Yale School of Medicine https://lnkd.in/ezj8qVqy

40

Conventional practices in the pharmaceutical industry can lead to less-than-optimal treatments because they fail to adequately customize drug types and dosages for individual patients. Recently, Philip Tagari, CSO at insitro, joined a16z founding general partner Vijay Pande, PhD to discuss how AI can help transform patient stratification from a one-size-fits-all approach to a more precise, personalized strategy, potentially increasing the effectiveness of treatments and improving patient outcomes. Listen on Raising Health: https://lnkd.in/gfmAMEzZ

18

Fantastic article written by Andrew Borenstein, Vinod Swarna, and Anuj Saxena from ZS. The piece highlights that "as #healthcare costs continue to rise, U.S. health plans must be more vigilant in ensuring the integrity of their claims payment processes and systems." Specifically, health plans should lean into payment integrity allowing them to reduce medical spend, shrink provider abrasion, as well as comply with regulations and contractual agreements. #AI offers a promising solution, but many companies have yet to embrace its potential, even as annual losses reach a staggering $935 billion! https://lnkd.in/eg2CBkaT

12

1 Comment

Member company Johnson & Johnson is actively using technology in different ways, In a time when chronic diseases are on the rise and people are living longer than ever before, novel solutions for better patient care are urgently needed. In healthcare’s next chapter, a new type of technology will play a bigger role than ever before. Enter artificial intelligence, or AI. Read more here. https://bit.ly/3VUKLMu

8

Unveiling the Future of Patient Care: Discover how our Proprietary Sepsis Prediction Model can revolutionize early detection and improve outcomes. Watch to learn how AI-driven insights are transforming the fight against sepsis in healthcare! Nauman Jaffar Douglas Slakey, MD,MPH SenSights.AI™ Abby Aboitiz #HealthcareInnovation #SepsisAwareness #AIinHealthcare #PatientSafety

1

1 Comment

Our CEO, Rajesh Devraj, participated in the Longwood Healthcare Leaders #MiamiCEO conference. On a panel with #biotech leaders, he shared insights on target and indication selection when translating science into medicine. More on our science here: https://bit.ly/3V5Vul7

22

#AI is revolutionizing the life sciences, from cognitive molecule research to streamlining biopharma manufacturing. This panel will explore how researchers and companies are using AI to accelerate cures, reshape business models, and transform patient care. 🎤 Speakers include: Audrey Greenberg, Center for Breakthrough Medicines Donna Conrey, SciMarOne Dave Latshaw II, PhD, MBA BioPhy Irene Rombel, BioCurie Walter R. T. Witschey, Sr., University of Pennsylvania Edward kim, Drexel University Matthew Stamm, Drexel University Join us at the Philly Builds Bio+ Third Annual Symposium for this groundbreaking discussion! 🔗 Register now: phillybuildsbio.org #PhillyBuildsBio #AIinHealthcare #LifeSciences #DigitalTransformation #AI

27

3 Comments

Great day for California Life Sciences (CLS) attending Physicians for a Healthy California, Health Equity Leadership Summit! Panelist, Maria Jison, MD, (Executive Director, Global Clinical Head, Fasenra) of member company AstraZeneca spoke to the strides they've made using their AIRE Mobile Unit as a “clinic on wheels” that brings trial screenings directly to patients in diverse communities. The mobile unit is equipped with exam rooms and staffed with healthcare professionals who are ready to pre-screen patients and book both an appointment and transportation for patients to visit the clinical trial site they’re referred to. Per Maria, "You can't be successful without community engagement and building trust. It's not enough to just show up in a bus.....you really need to be part of the community. A multi-pronged engagement campaign is required. Outreach alone isn't enough — you need to partner with other organizations that are part of the community and trusted." #EquitableResources #PhysiciansForAHealthyCalifornia #HealthEquity

19

1 Comment